1. Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
   Alessandro Testori et al, 2008, Journal of Clinical Oncology CrossRef
2. Differences in Glycosylation Patterns of Heat Shock Protein, gp96: Implications for Prostate Cancer Prevention
   Robert Suriano et al, 2005, Cancer Research CrossRef
3. Peripheral Blood Mononuclear Cell Proliferation to Heat Shock Protein–70 Derived from Autologous Lung Carcinoma
   Alain Michils et al, 2002, American Journal of Respiratory and Critical Care Medicine CrossRef